摘要
目的探讨微柱凝胶技术筛检不规则抗体在输血治疗中的临床意义。方法对医院1357例住院输血患者利用微柱凝胶技术筛检不规则抗体。结果在1357例患者中，阳性患者6例，阳性率为0-4％，其中IgG阳性2例，抗-E阳性2例，抗-K阳性1例，慢性淋巴细胞白血病引起1例。结论微柱凝胶技术筛检不规则抗体保持了传统的抗人球蛋白法的全部优点，又克服了其试验的繁琐耗时的缺点，可以及早准确发现阳性结果，选择合适的血液，从而防止因为输注含有某抗体相应抗原的血而引起溶血性输血反应，保证输血安全。
Objective micro-gel technology screening for irreguLar antibodies of clinical significance in transfusion therapy. Methods The hospital from 1357 cases of blood transfusion in patients with micro-gel technology screening for irreguLar anti- bodies.ResuLts 1357 patients,positive patients（n=6）,the positive rate of 0.4%,including two cases IgG positive,anti-E2,anti-KI, cases,caused by chronic lymphocytic leukemia patients.Conclusion The micro-gel technology screening irreguLar antibodies to maintain all the advantages of the traditional anti-human globuLin method,but also to overcome the shortcomings of the trial cumbersome and time-consuming,early and accurate detection of positive resuLts,select the appropriate blood,thus to prevent the infusion with a corresponding antibody antigen blood cause hemolytic transfusion reactions,and to ensure the safety of blood transfusion.
出处
《中国药业》
CAS
2013年第A02期99-99,共1页
China Pharmaceuticals
关键词
溶血性输血反应
微柱凝胶法
不规则抗体
筛检
hemolytic transfusion reaction
microcolumn gel
irreguLar antibody screening.
